NASDAQ:TCRX - US89854M1018 - Common Stock
The current stock price of TCRX is 1.75 USD. In the past month the price increased by 2.34%. In the past year, price decreased by -68.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.01 | 374.37B | ||
AMGN | AMGEN INC | 13.16 | 154.47B | ||
GILD | GILEAD SCIENCES INC | 14.56 | 139.85B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.67 | 102.81B | ||
REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.59B | ||
ARGX | ARGENX SE - ADR | 76.2 | 43.23B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.69 | 39.47B | ||
INSM | INSMED INC | N/A | 30.71B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.19B | ||
NTRA | NATERA INC | N/A | 23.24B | ||
BIIB | BIOGEN INC | 8.72 | 20.47B |
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 210 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
TSCAN THERAPEUTICS INC
830 Winter Street
Waltham MASSACHUSETTS US
CEO: David Southwell
Employees: 201
Phone: 18573999500
The current stock price of TCRX is 1.75 USD. The price decreased by -2.78% in the last trading session.
The exchange symbol of TSCAN THERAPEUTICS INC is TCRX and it is listed on the Nasdaq exchange.
TCRX stock is listed on the Nasdaq exchange.
14 analysts have analysed TCRX and the average price target is 8.67 USD. This implies a price increase of 395.43% is expected in the next year compared to the current price of 1.75. Check the TSCAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TSCAN THERAPEUTICS INC (TCRX) has a market capitalization of 99.31M USD. This makes TCRX a Micro Cap stock.
TSCAN THERAPEUTICS INC (TCRX) currently has 201 employees.
TSCAN THERAPEUTICS INC (TCRX) has a support level at 1.74 and a resistance level at 1.8. Check the full technical report for a detailed analysis of TCRX support and resistance levels.
The Revenue of TSCAN THERAPEUTICS INC (TCRX) is expected to grow by 182.46% in the next year. Check the estimates tab for more information on the TCRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TCRX does not pay a dividend.
TSCAN THERAPEUTICS INC (TCRX) will report earnings on 2025-11-10, before the market open.
TSCAN THERAPEUTICS INC (TCRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.09).
The outstanding short interest for TSCAN THERAPEUTICS INC (TCRX) is 3.55% of its float. Check the ownership tab for more information on the TCRX short interest.
ChartMill assigns a technical rating of 4 / 10 to TCRX. When comparing the yearly performance of all stocks, TCRX is a bad performer in the overall market: 94.33% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to TCRX. While TCRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months TCRX reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS decreased by -3.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.81% | ||
ROE | -77.4% | ||
Debt/Equity | 0.18 |
14 analysts have analysed TCRX and the average price target is 8.67 USD. This implies a price increase of 395.43% is expected in the next year compared to the current price of 1.75.
For the next year, analysts expect an EPS growth of -0.78% and a revenue growth 182.46% for TCRX